Redx, a clinical-stage biotechnology company focused on discovering and developing novel, small molecule, targeted therapeutics for the treatment of cancer and fibrotic disease, announced preclinical data for its lead fibrosis asset, RXC007, and the Discodin Domain Receptor (DDR)1/2 discovery programme. The data were from preclinical models of pancreatic ductal adenocarcinoma (PDAC) and triple negative breast […]